Autres langues Armata Pharmaceuticals, Inc.

Actions

ARMP

US04216R1023

Recherche biotechnologique et médicale

Marché Fermé - NYSE 22:00:00 07/10/2026			Varia. 5j.	Varia. 1 janv.
3,810 ^USD	-1,04%		+3,81%	-39,33%

21/09	Armata Pharmaceuticals, Inc. présente des données sur la diversité génétique définie d'AP-SA02 lors de l'ISSSI 2026	CI
14/09	Armata Pharmaceuticals : la FDA accorde le statut de 'Breakthrough Therapy' à l'AP-SA02	MT

Autres langues

07/10	Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
23/09	Armata Pharmaceuticals Receives Additional Non-Dilutive Funding To Support AP-SA02 Phase 3 Development
23/09	Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
21/09	Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
21/09	Armata Pharmaceuticals, Inc. Presents Data On Defined Genetic Diversity In AP-SA02 At ISSSI 2026
14/09	Armata Pharma Shares Rise on FDA Breakthrough Therapy Designation for Antibacterial Treatment
14/09	Armata Pharmaceuticals' AP-SA02 Gets FDA Breakthrough Therapy Designation
14/09	Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
14/09	Armata Pharmaceuticals Receives FDA Breakthrough Therapy Designation For AP-SA02
10/09	Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
03/09	Armata Pharmaceuticals Announces New Publication Advancing Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
03/09	Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
12/08	Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
12/08	Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/07	Armata Pharmaceuticals, Inc. Appoints David House as Chief Financial Officer, Effective July 17, 2026
20/07	Armata Pharmaceuticals Names David House as CFO; Advances Staphylococcus Aureus Treatment Candidate
20/07	Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
13/07	Armata Pharmaceuticals Receives Agreement From FDA On Initial Pediatric Study Plan For AP-SA02 For The Treatment Of Complicated Staphylococcus Aureus Bacteremia
13/07	Armata Pharma Reaches FDA Agreement on Pediatric Study Plan for AP-SA02
13/07	Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
29/06	Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell Small Cap Comp Growth Benchmark
29/06	Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell 2500 Growth Benchmark
29/06	Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell 2000 Index
29/06	Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) dropped from Russell Microcap Value Benchmark Index
29/06	Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell 2000 Growth Benchmark